FMISO PET Study of Glioblastoma

NACompletedINTERVENTIONAL
Enrollment

11

Participants

Timeline

Start Date

February 28, 2014

Primary Completion Date

April 30, 2019

Study Completion Date

April 30, 2019

Conditions
Recurrent Glioblastoma
Interventions
DEVICE

FMISO PET

DEVICE

MRI

"MR scans will be performed with the same sequences and in the same order during each visit, including T1- and T2-weighted volumetric images, fluid attenuated inversion recovery (FLAIR), contrast agent enhanced T1-weighted permeability, diffusion tensor imaging (DTI), T2/T2\*-weighted perfusion scans, and MR Spectroscopy. The Autoalign package available from the manufacturer will be used to achieve the same slice prescription in the same patient at each visit. Each MRI will last 60-75 minutes versus 45 minutes for standard brain MRIs."

DRUG

Bevacizumab

A cycle is defined as 28 days (1 month). The study duration is 12 months (12 cycles). Patients will be treated after 12 months or at the time of progression per discretion of their responsible physician.

DRUG

CCNU

A cycle is defined as 28 days (1 month). The study duration is 12 months (12 cycles). Patients will be treated after 12 months or at the time of progression per discretion of their responsible physician.

Trial Locations (1)

01852

Massachusetts General Hospital, Boston

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Massachusetts General Hospital

OTHER

NCT02076152 - FMISO PET Study of Glioblastoma | Biotech Hunter | Biotech Hunter